Abdominal obesity is among the clinically well-documented risk factors in the development of type 2 diabetes. The role of weight loss in diabetes management is defined by clinical guidelines; however, losing weight and keeping it off is a challenging process for most patients.
The Effect of Weight Loss on Diabetes
Even losing 5–10% of body weight can significantly improve blood sugar control:
- A 0.5–1.0% reduction in HbA1c
- A decrease in insulin resistance
- A reduction in the antidiabetic medication dose in some patients
Cases of type 2 diabetes entering remission with 10–15% weight loss have been reported (provided regular health monitoring).
The Data the Allurion Program Offers Clinicians
In the 1,770-patient study by Ienca et al., an average of 14.9% TBWL (total body weight loss) was documented (Obes Surg 2020, PMID: 32279182).
A multicenter retrospective study (2025, PMID: 41037243) confirmed the safety profile of Allurion use in metabolic comorbidities.
These figures can be evaluated by clinicians in patients with diabetes; however, the individual treatment decision rests with the specialist physician.
Combination with GLP-1
GLP-1 receptor agonists (such as semaglutide) are used for both weight and blood sugar control. However, when these medications are discontinued, an average regain of +5.63 kg was observed (18 RCTs, n=3,771, EClinicalMedicine 2025, PMID: 41399474).
The combined Allurion + GLP-1 protocol may reduce dependence on medication while making the balloon's behavioral component lasting. This area is the subject of active research.
Who Can It Be Considered For?
- Patients with a BMI ≥27 and a type 2 diabetes diagnosis
- Patients with a BMI ≥30 who want to reduce their oral antidiabetic dose
- Patients who want to support GLP-1 therapy
- Diabetic patients preparing for bariatric surgery
Contraindication: Eligibility for insulin-dependent (type 1) diabetes is evaluated separately.
Recommended Follow-Up Protocol for the Patient
Blood sugar monitoring is critically important throughout the program:
- Fasting glucose and HbA1c measurement before starting
- Monthly blood sugar monitoring
- Medication doses should be managed by a physician (there may be a risk of hypoglycemia with weight loss)
- HbA1c reassessment at the end of the program
Conclusion
The Allurion Program may be part of a holistic approach in obesity-related type 2 diabetes. The clinical decision should be made in coordination with a specialist endocrinologist or internal medicine physician.
Fill out the form for a free assessment →
This content is for informational purposes and does not constitute medical advice. For diabetes management, be sure to consult your specialist physician. Individual results may vary.
Related Topics
- The Relationship Between Obesity and Diabetes →
- Weight Loss with a Gastric Balloon →
- GLP-1 and Gastric Balloon Combination →
- Free Assessment →
An Authorized Clinic in a City Near You
You can undergo the Allurion Program at more than 60 authorized clinics across Türkiye. For clinics in major cities:
Clinical Sources
Related Articles
Who Is the Smart Capsule Not Suitable For? Contraindications
Who is the Allurion Smart Capsule (swallowable gastric balloon) not suitable for? Absolute contraindications, conditions requiring caution, and how eligibility is determined through a physician's evaluation.
What Is the Swallowable Gastric Balloon? Who Can Get It in Türkiye?
What is the swallowable gastric balloon, how does it work, and who is it for? A comprehensive guide to the Allurion Balloon, which requires no endoscopy.
Who Is the Gastric Balloon For? Indications and Contraindications
Who is the Allurion swallowable gastric balloon for? A comprehensive guide to BMI criteria, eligibility conditions, contraindications, and special situations.
Related Pages
Which method is right for you?
Let our specialist physicians evaluate you free of charge.
Free Pre-Assessment →